Renal cell carcinoma
- PMID: 18391630
- DOI: 10.1097/CCO.0b013e3282f9782b
Renal cell carcinoma
Abstract
Purpose of review: The recent contributions to renal cell carcinoma in the fields of molecular biology and the expanded use of molecularly targeted agents will be reviewed. This study is intended to update prognostic and therapeutic decision-making data and provide perspective on advances in understanding the molecular biology of this disease.
Recent findings: Updates to the currently used prognostic algorithms for renal cell carcinoma are needed, and recently verified prognostic nomograms will be discussed. This comes in the wake of numerous advances in the use of molecularly targeted drugs, which will be reviewed. Finally, advancements in understanding the biology of renal cell carcinoma include the discovery of von Hippel-Lindau associated mechanisms involved in renal cyst formation and renewed appreciation for the influence of this pathway on the tumor cell glucose utilization profile.
Summary: Renal cell carcinoma continues to evolve swiftly with the approval of new agents and the maturation of clinical trials to provide relevant structure to treatment decisions. This study will give an overview of the latest concepts in the epidemiology and biology of renal cell carcinoma and provide current surgical and systemic updates for managing renal cell carcinoma.
Similar articles
-
Targeted therapy in renal cell carcinoma.Curr Opin Urol. 2008 Sep;18(5):481-7. doi: 10.1097/MOU.0b013e32830a70cf. Curr Opin Urol. 2008. PMID: 18670271 Review.
-
Renal cell carcinoma.Curr Opin Oncol. 2009 May;21(3):266-71. doi: 10.1097/CCO.0b013e32832a05c8. Curr Opin Oncol. 2009. PMID: 19339887 Review.
-
Continuing response to subsequent treatment lines with tyrosine kinase inhibitors in an adolescent with metastatic renal cell carcinoma.J Pediatr Hematol Oncol. 2011 Jul;33(5):e176-9. doi: 10.1097/MPH.0b013e3182028fd9. J Pediatr Hematol Oncol. 2011. PMID: 21552143
-
The therapy of kidney cancer with biomolecular drugs.Cancer Treat Rev. 2010 Nov;36 Suppl 3:S16-20. doi: 10.1016/S0305-7372(10)70015-3. Cancer Treat Rev. 2010. PMID: 21129605 Review.
-
Molecularly targeted therapy in renal cell carcinoma.Expert Rev Anticancer Ther. 2005 Dec;5(6):1031-40. doi: 10.1586/14737140.5.6.1031. Expert Rev Anticancer Ther. 2005. PMID: 16336094 Review.
Cited by
-
Expression profiling and clinicopathological significance of DNA methyltransferase 1, 3A and 3B in sporadic human renal cell carcinoma.Int J Clin Exp Pathol. 2014 Oct 15;7(11):7597-609. eCollection 2014. Int J Clin Exp Pathol. 2014. PMID: 25550796 Free PMC article.
-
Cytoplasmic expression of Twist1, an EMT-related transcription factor, is associated with higher grades renal cell carcinomas and worse progression-free survival in clear cell renal cell carcinoma.Clin Exp Med. 2018 May;18(2):177-190. doi: 10.1007/s10238-017-0481-2. Epub 2017 Dec 4. Clin Exp Med. 2018. PMID: 29204790
-
6-Shogaol Suppresses 2-Amino-1-Methyl-6-Phenylimidazo [4,5-b] Pyridine (PhIP)-Induced Human 786-O Renal Cell Carcinoma Osteoclastogenic Activity and Metastatic Potential.Nutrients. 2019 Sep 28;11(10):2306. doi: 10.3390/nu11102306. Nutrients. 2019. PMID: 31569368 Free PMC article.
-
A glance at the emerging diagnostic biomarkers in the most prevalent genitourinary cancers.Saudi J Biol Sci. 2022 Apr;29(4):2072-2084. doi: 10.1016/j.sjbs.2022.01.017. Epub 2022 Jan 15. Saudi J Biol Sci. 2022. PMID: 35531253 Free PMC article. Review.
-
Low level of Cyclin-D1 correlates with worse prognosis of clear cell renal cell carcinoma patients.Cancer Med. 2019 Aug;8(9):4100-4109. doi: 10.1002/cam4.2313. Epub 2019 Jun 10. Cancer Med. 2019. PMID: 31183974 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials